Biomea Fusion (BMEA) Net Income towards Common Stockholders (2020 - 2026)
Biomea Fusion (BMEA) posted Net Income towards Common Stockholders of -$12.3 million for Q1 2026, up 26.95% sequentially from -$16.9 million in Q4 2025, and up 57.82% YoY from -$7.8 million in Q1 2025.
Biomea Fusion (BMEA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$12.3 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 57.82% year-over-year to -$12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.4 million (up 48.43% YoY) and the FY2025 annual result came in at -$214.9 million, up 14.82% from the prior year.
- Net Income towards Common Stockholders improved to -$12.3 million in Q1 2026 per BMEA's latest filing, from -$16.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$12.3 million in Q1 2026 and troughed at -$45.3 million in Q3 2023.
- A 5-year average of -$27.9 million and a median of -$29.3 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders slumped 145.42% in 2023, then surged 57.82% in 2026.
- Over 5 years, Net Income towards Common Stockholders stood at -$25.5 million in 2022, then plunged by 35.3% to -$34.5 million in 2023, then grew by 14.68% to -$29.4 million in 2024, then jumped by 42.56% to -$16.9 million in 2025, then grew by 26.95% to -$12.3 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$12.3 million, -$16.9 million, and -$16.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | -12.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.45 Mn |
| Mar 31, 2026 | -12.34 Mn |
| Dec 31, 2025 | -16.90 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Jun 30, 2025 | -20.74 Mn |
| Mar 31, 2025 | -29.26 Mn |
| Dec 31, 2024 | -29.42 Mn |
| Sep 30, 2024 | -32.79 Mn |
| Jun 30, 2024 | -37.28 Mn |
| Mar 31, 2024 | -43.30 Mn |
| Dec 31, 2023 | -34.48 Mn |
| Sep 30, 2023 | -45.34 Mn |
| Jun 30, 2023 | -42.79 Mn |
| Mar 31, 2023 | -29.89 Mn |
| Dec 31, 2022 | -25.49 Mn |
| Sep 30, 2022 | -23.07 Mn |
| Jun 30, 2022 | -17.43 Mn |
| Mar 31, 2022 | -16.54 Mn |
| Dec 31, 2021 | -14.86 Mn |
| Sep 30, 2021 | -15.99 Mn |